4SCAR2.0 therapy for the management of post-transplantation relapse of B-cell acute lymphoblastic leukemia

4SCAR2.0 therapy for the management of post-transplantation relapse of B-cell acute lymphoblastic leukemia

IntroductionAllogeneic hematopoietic stem cell transplantation (allo-HCT) is a standard treatment for relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). However, about 30-40% of patients still relapse after HCT. Chimeric antigen receptor-modified T-cell (CAR-T) therapy has been pro...

Full description

Bibliographic Details
Main Authors: Rui Zhang, Juan Xiao, Yuan Sun, Sanfang Tu, Yuhua Li, Leping Zhang, Yifei Cheng, Song Xue, Yongping Zhang, Bin Wang, Huyong Zheng, Nobuhiro Nishio, Yoshiyuki Takahashi, Seiji Kojima, Yingying Wang, Biljana Horn, Lung-Ji Chang
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-11-01
Series:Frontiers in Hematology
Subjects:
CAR-T
B-ALL
transplantation
CD19
GvHD
Online Access:https://www.frontiersin.org/articles/10.3389/frhem.2023.1251622/full

Internet

https://www.frontiersin.org/articles/10.3389/frhem.2023.1251622/full

Similar Items